What do patients and clinicians really need from the next generation of IBD therapies?

New therapies in Ulcerative Colitis and Crohn’s Disease faced uncertainty around the value signals that mattered most, and in establishing and demonstrating the value of novel mechanisms of action set against uncertain unmet need in a crowded market.

A comprehensive insights and evidence development programme was implemented across multiple countries to gather unmet needs, value drivers, and outcome priorities.